Which has the lower trailing P/E, AMRX or CHE?

CHE has the lower trailing P/E: AMRX trades at 41.68 and CHE at 25.53. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, AMRX or CHE?

Over the past five years, AMRX grew revenue faster — AMRX at a 8.67% CAGR versus CHE at 4.12%.

Does AMRX or CHE pay a bigger dividend?

CHE pays a dividend (0.49% yield), while AMRX has no payments in the available dividend history.

Is AMRX or CHE more profitable?

CHE runs the higher net margin — AMRX at 5.05% versus CHE at 10.60%.

How have AMRX and CHE total returns compared?

Over the past 10 years, AMRX delivered -1.73% and CHE delivered 14.19% annualized total return. Past performance doesn't predict future results.

Amneal Pharmaceuticals, Inc. (AMRX) vs Chemed Corporation (CHE)

A side-by-side comparison of Amneal Pharmaceuticals, Inc. and Chemed Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AMRX

Amneal Pharmaceuticals, Inc.

$6.49B

$20.32HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT

CHE

Chemed Corporation

$6.65B

$508.55HealthcareDelayed quote: Oct 6, 2026, 10:09 AM EDT

Total return — AMRX vs CHE

growth of $100 · dividends reinvested · last 10y

AMRX -13.6% (-1.5%/yr)CHE +280.9% (+14.3%/yr)CHE compounded faster over this window

AMRX CHE

AMRX vs CHE: by the numbers

•CHE is the larger company ($6.65B vs $6.49B market cap).
•CHE trades at the lower trailing earnings multiple (25.53 vs 41.68 P/E), one valuation lens rather than an overall verdict.
•CHE converts more revenue to profit (10.60% vs 5.05% net margin).
•AMRX grew revenue faster over the past five years (8.67% vs 4.12% CAGR).
•CHE pays a dividend (0.49% yield), while AMRX has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	AMRX	CHE
P/E ratio	41.68	25.53
Forward P/E	19.85	19.95
P/S ratio	2.08	2.56
P/B ratio	196.49	8.00
EV / EBITDA	15.32	16.69
FCF yield	1.28%	4.87%

Profitability

Metric	AMRX	CHE
Gross margin	39.32%	30.44%
Operating margin	12.93%	13.46%
Net margin	5.05%	10.60%
ROE	476.51%	33.11%
ROIC	13.45%	19.48%

Dividends

Metric	AMRX	CHE
Dividend yield	N/A	0.49%
Payout ratio	N/A	12.55%

Growth (annualized)

Metric	AMRX	CHE
Revenue CAGR (5Y)	8.67%	4.12%
EPS CAGR (5Y)	-17.72%	-1.65%
FCF CAGR (5Y)	-14.46%	-5.44%
Total return CAGR (5Y)	30.25%	3.58%

Frequently asked

Which has the lower trailing P/E, AMRX or CHE?: CHE has the lower trailing P/E: AMRX trades at 41.68 and CHE at 25.53. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, AMRX or CHE?: Over the past five years, AMRX grew revenue faster — AMRX at a 8.67% CAGR versus CHE at 4.12%.
Does AMRX or CHE pay a bigger dividend?: CHE pays a dividend (0.49% yield), while AMRX has no payments in the available dividend history.
Is AMRX or CHE more profitable?: CHE runs the higher net margin — AMRX at 5.05% versus CHE at 10.60%.
How have AMRX and CHE total returns compared?: Over the past 10 years, AMRX delivered -1.73% and CHE delivered 14.19% annualized total return. Past performance doesn't predict future results.

Go deeper

Full AMRX analysis Full CHE analysis Interactive comparison tool

Dig into the metrics

Amneal Pharmaceuticals P/E ratio Chemed P/E ratio Chemed dividend yield Amneal Pharmaceuticals ROE Chemed ROE Amneal Pharmaceuticals operating margin Chemed operating margin Amneal Pharmaceuticals revenue growth Chemed revenue growth Amneal Pharmaceuticals free cash flow Chemed free cash flow

Amneal Pharmaceuticals & Chemed appear in these rankings

Highest ROE Stocks Highest ROIC Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.